BiotechTV - News Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
May 6, 2025
Pierluigi Paracchi, Co-Founder and CEO of Genenta Science, shares insights on the company's groundbreaking cell therapy approach for renal cell carcinoma. He explains the recent €20 million funding from ENEA Tech and Biomedical, highlighting the innovative convertible bond structure. Paracchi updates listeners on clinical trials and the exciting prospects for patient dosing, emphasizing the challenges and opportunities within the European biotech landscape. The conversation also touches on the impact of this investment on Genenta's future and advancements in the broader field of cancer therapy.
AI Snips
Chapters
Transcript
Episode notes
Targeted Cell Therapy Innovation
- Genenta Science uses engineered hematopoietic stem cells to deliver anti-tumor proteins directly into the tumor microenvironment.
- This controlled gene expression avoids systemic toxicity while targeting tumor-infiltrating immune cells effectively.
Innovative Funding Amid Tough Market
- Despite a toxic market for biotech funding, Genenta secured €20 million from an Italian government agency via a convertible bond.
- This deal reflects a market undervaluation of Genenta's true progress and offers conversion rights after three years.
Promising Clinical Trial Progress
- Genenta has treated 24 glioblastoma patients with no gene therapy-related toxicity and observed improved survival rates compared to historical data.
- Encouraged by reprogramming immune responses, they are now expanding to metastatic renal cell carcinoma combined with checkpoint inhibitors.